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Activation of renin synthesis is dependent on intact nitric oxide
production
PIERRE-LOUIS THARAUX, JEAN-CLAUDE DUSSAULE, MARIE-DOMINIQUE PAUTI, YVES VASSITCH,
RAYMOND ARDAILLOU, and CHRISTOS CHATZIANTONIOU
INSERM U.64, Hôpital Tenon, Paris, France
Activation of refill synthesis is dependent on intact nitric oxide
production. The present study investigated whether or not nitric oxide
(NO) synthesis mediates mechanisms regulating activation of renin for-
mation. Studies were performed on afferent arterioles freshly isolated
from the rat kidney. We have shown previously that this preparation is a
useful model to study regulation of renin synthesis and secretion. The
expression of renin mRNA was assessed by ribonuclease protection assay,
and total renin content and renin secretion by radioimmunoassay. In
afferent arterioles isolated from rats treated with the angiotensin-convert-
ing enzyme inhibitor ramipril, renin mRNA levels, total renin content and
renin secretion were increased threefold compared to untreated controls.
Inhibition of NO-synthase by N°-nitro-L-arginine methyl ester (L-
NAME) in the ramipril-treated rats, abolished the increase in renin
mRNA levels, total renin content and renin secretion. In other animals,
furosemide, a diuretic acting on macula densa cells, activated renin
synthesis to a level similar to that found in the ramipril-trcated group.
Addition of L-NAME to the furosemide-treated rats suppressed the
increases in renin mRNA levels, total renin content and renin secretion,
suggesting that NO acts on renin activation by a mechanism independent
of angiotensin II. In separate experiments, the inhibitory effect of L-
NAME on the activation of renin secretion was abolished when afferent
arterioles were treated with nicardipine, an L-type Ca2 channel blocker,
suggesting that the suppression of renin activation during NO inhibition is
due to increased Ca2 entry. Since endothelin is a potent mediator of
Ca2 influx and an inhibitor of renin release, we tested whether or not
endothelin could be involved in the inhibitory effect of L-NAME on renin
secretion. Application of the endothelin receptor antagonist, bosentan, in
vitro mimicked the effect of nicardipine. In addition, bosentan coadmin-
istered with L-NAME in vivo blunted the inhibitory effect of L-NAME and
restored the increases in renin mRNA level, synthesis and secretion.
These data indicate that the physiological mechanism(s) regulating acti-
vation of renin synthesis and secretion are impaired during NO inhibition,
probably because of increased Ca2 influx. This increase in calcium flux is
mediated at least partially by the action of endothelin.
The renin-angiotensin system (RAS) plays a major role in the
regulation of renal and cardiovascular functions. It is well known
that renin release is influenced by changes in arterial pressure,
sodium intake, activity of sympathetic nerves, and plasma concen-
tration of several hormones [1]. However, the cellular mecha-
nisms controlling renin secretion are not yet fully understood. In
particular, conflicting data are reported about nitric oxide (NO)
influences on renin release and/or synthesis and the mechanisms
involved. Early reports were in favor of an inhibitory role of NO
on renin secretion through guanylate cyclase activation. Thus, NO
donors inhibited renin release in rat cortical slices, whereas
inhibition of NO synthesis increased plasma renin activity in
conscious dogs and anesthetized rats [2—4]. However, other recent
investigations revealed a more complex interaction of NO with
renin secretion. For example, in cultured mouse juxtaglomerular
cells, NO donors had a dual effect on renin secretion: an early
inhibitory effect, probably due to stimulation of guanylate cyclase,
and a late stimulatory effect that was mediated by an as yet
unidentified pathway [5]. In addition, inhibition of NO synthesis
reduced plasma renin levels and renin release in high RAS activity
models (the anesthetized or furosemide-treated rat, and the
isolated perfused rat kidney) [6—8]. It is interesting to note that
the most widely used experimental approach in the NO-RAS
interaction studies was to inhibit endogenous NO synthesis. It is
possible that some of the effects of NO blockade on renin release
were due to an altered balance between NO and vasoconstrictors
such as angiotensin II or endothelin (well-known activators of
Ca2 influx and inhibitors of renin formation [1]). No data have
been reported to date evaluating a possible involvement of these
renal vasoeonstrictors on the regulation of renin secretion and
synthesis when NO production is inhibited.
Recently, we developed a preparation of afferent arterioles
freshly isolated from the rat kidney to study the properties of
angiotensin II receptors [9]. In subsequent studies we refined this
vascular preparation to study the autocrine and paracrine regula-
tion of the RAS [10]. In addition, we have observed that inhibition
of NO blunted the in vitro, forskolin-induced increase of renin
secretion [11].
The purpose of the present studies was to evaluate whether or
not and by which mechanism(s) NO affects the activity of the RAS
when stimulated by various mechanisms. For this reason, renin
synthesis was stimulated by converting enzyme inhibition or by a
diuretic acting on the macula densa cells, with or without inhibi-
tion of endogenous NO synthesis. Measurements of renin secre-
tion, tissue content and mRNA levels were performed in the
above-mentioned model of isolated afferent arterioles. Our find-
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ings demonstrate that NO is necessary for an effective activation
of renin formation. Inhibition of NO synthesis appears to impair
renin secretion and synthesis through changes in cytosolic calcium
concentration mediated by endothelin-indueed activation of dihy-
dropyridine-sensitive calcium-entry channels.
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Methods
Animal treatment
Male Sprague-Dawley rats were maintained on a normal salt
diet and weighed 150 to 200 g at the time of the experiments.
Animals had free access to chow and tap water. To activate renin
synthesis, rats were treated with ramipril (10 mg/kg/day), an
angiotensin converting enzyme inhibitor or furosemide (20 mg/
kg/day), a diuretic agent that inhibits Na4 /K/2Cl cotransport in
macula densa cells. In some of the ramipril-treated rats, N-nitro-
L-arginine methyl ester (L-NAME), a NO synthase inhibitor, was
coadministered at a dose of 10 mg/kg/day. In previous studies we
found that this dose is the minimum required for a sufficient
blockade of endogenous NO synthesis in the rat without altering
the mean arterial pressure till. In a separate group of ramipril- or
ramipril + L-NAME-treated rats, bosentan 30 mg/kg/day (an
endothelin receptor antagonist) was administered. All in vivo
treatments lasted five days. Previous studies revealed that this
duration is enough to activate renin synthesis and release, and to
block NO without affecting blood pressure [11].
In some ramipril- or ramipril + L-NAME-treated rats, the
L-type channel calcium blocker, nicardipine, or the mixed endo-
thelin receptor (ETA and ETB) antagonist, bosentan [121, were
administered into the kidneys at the concentration of 1 and 10 M,
respectively, immediately before the kidneys were removed. All
subsequent steps until the isolation of afferent arterioles were
carried out in the presence of 1 /.LM nicardipine or 10 /.tM bosentan.
Six to 12 rats were used to isolate afferent arterioles for each
experiment. Each series of experiments consisted of at least four
independent experiments.
Measurement of blood pressure
Systolic blood pressure was measured by the tail-cuff method
(W+W electronic recorder 8005; Apelab, Bagneux, France).
Measurements were done before, and five days after the first
administration of drugs.
Isolation of afferent arterioles
The technique to isolate afferent arterioles from the rat kidney
was the same as previously described [9—il]. Briefly, in rats
anesthetized with pentobarbital, a midline abdominal incision was
made, and the abdominal aorta was cannulated below the renal
arteries. The aorta above the kidney was ligated, the left renal vein
was cut, and kidneys were perfused with iced isotonic saline
solution until all blood was removed. Thereafter the kidneys were
perfused with a magnetized iron oxide suspension (1% Fe3O4 in
isotonic saline). All subsequent steps of isolation were performed
at 4°C. The kidneys were removed, decapsulated, and the cortex
was dissected from the medulla. Cortical tissue was homogenized
with a Polytron homogenizer, and the iron oxide-loaded tissues
(renal vessels and glomeruli) were removed from the crude
homogenate with the aid of a magnet. Affcrent arterioles were
separated from larger vessels and glomeruli using repetitive
passages through needles and sieves of decreasing diameter sizes
(20 to 23 gauge and 150 to 90 j.tm, respectively). The microvessels
were recovered from the top of the 125 m sieve. To determine if
parts of afferent arterioles stayed attached to glomeruli during the
separation process, glomeruli were collected in parallel using a 75
j.tm sieve and examined under light microscopy. Only a minor part
of isolated glomeruli (< 3%) had an attached portion of an
afferent arteriole. Vascular preparations containing > 90% of
afferent arterioles were retained for subsequent experiments.
Protein content was estimated according to Bradford's method
[13].
Renin release evaluation
Aliquots of microvessels (100 to 200 j.tg of protein) were
incubated at 37°C in a final volume of 0.5 ml of RPMI medium. To
determine the intracellular renin content, microvessels were
treated with 0.1% Triton X100 for 30 minutes at room tempera-
ture. Total renin content was defined as the sum of released renin
and intracellular renin content. Renin activity was measured by
radioimmunoassay as the amount of angiotensin I (Ang I) pro-
duced by incubation of supernatants with an excess of rat renin
substrate (plasma of binephrectomized rats). Renin activity was
expressed in nanograms of Ang I generated per hour of incuba-
tion per milligram of protein of afferent arterioles. Measurements
of renin secretion and synthesis were performed after 30 minutes,
two hours and four hours incubation of afferent arterioles in
RPMI, according to previously published data [11]. Three to six
measurements were performed per condition/per experiment.
Measurement of preprorenin mRNA expression
The method to determine the mRNA of preprorenin from rat
afferent arterioles was similar to that previously described [14].
Briefly, total RNA was extracted from the vessels according to the
protocol of Chomczynski and Sacchi [15]. Renin mRNA was
measured by ribonuclease protection assay. A preprorenin com-
plementary RNA probe containing 296 bp of exons I and II (made
from a pGEM-4 vector carrying a PstI-KpnI restriction fragment
of a rat preprorenin eDNA) was generated by transcription with
SP6 RNA polymerase. Transcripts were labeled with 32P-UTP (15
TBq/mmol, ICN). For each sample, increasing amounts of total
RNA (from 10 to 30 jig) were hybridized with the renin probe.
The amount of total renal RNA commonly used for renin RPA is
20 jig [7, 14, 161. Since our studies were performed using afferent
arterioles (a tissue of higher concentration in renin than whole
kidney) and in conditions of activation of renin synthesis, we
tested increasing amounts of total RNA to verify that saturation
of the signal did not occur. Ribonuclease digestion was carried out
with A and T RNase, and the protected mRNA fragments were
purified by phenol-chloroform extraction, ethanol precipitation
and electrophoresis in a 8% polyacrylamide gel. After autoradiog-
raphy of the dried gels for 12 to 48 hours, bands representing
protected renin mRNA fragments were quantified by densitome-
try (Adobe Photoshop System) and by measurement of radioac-
tivity (32P, after excision of bands) on a liquid scintillation counter
(1211 Rackbeta, LKB). In each hybridization, a renin mRNA
standard was included consisting of RNA extracted from afferent
arterioles of control Sprague-Dawley rats.
Statistical methods
Statistical analyses were performed using the Statview software
package. Results with P < 0.05 were considered statistically
significant. All values are means s.
Results
A primary goal was to investigate whether or not NO is involved
in the physiological mechanisms producing activation of the RAS.
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The design was to stimulate renin formation and evaluate re-
sponses to inhibition of NO synthesis. To this end, animals were
treated with ramipril, an angiotensin-converting enzyme inhibitor
and potent activator of renin synthesis and secretion, and L-
NAME, a potent inhibitor of NO-synthase. Treatment of rats with
these agents did not change body or kidney weights (data not
shown). In rats treated with ramipril, systolic blood pressure did
not change compared to control values (106 6 vs. 120 6 mm
Hg, P > 0.2). When ramipril and L-NAME were administered
simultaneously, systolic blood pressure increased slightly (135 8
vs. 120 6 mm Hg, P > 0.5), and increased significantly
compared to ramipril-treated rats (135 8 vs. 106 6 mm Hg,
P < 0.01).
Since differences in secretion, tissue content and mRNA of
renin among animal groups were similar and were independent of
the period of afferent arteriole incubation (30 mm, 2 or 4 hr), data
are presented for the two-hour time period to avoid unnecessary
repetition. Treatment of the animals with the angiotensin-con-
verting enzyme inhibitor to block angiotensin II formation mark-
edly activated renin synthesis. Renin secretion and tissue renin
content in afferent arterioles isolated from ramipril-treated rats
increased two- to threefold compared to controls (18,524 1,715
vs. 6,126 754 and 61,452 7,540 vs. 24,587 2,359 ng/mg/hr,
for secretion and tissue content, respectively, P < 0.01; Fig. 1A).
Similar increases were observed in the renin mRNA levels
extracted from the afferent arterioles of the ramipril-treated rats.
The protected fragment of renin mRNA from the ramipril-treated
group was threefold higher than control in all tested concentra-
tions of total RNA (Fig. IB).
Inhibition of NO production by L-NAME completely blocked
the ramipril-induced activation of renin formation since mRNA
levels, tissue content and secretion of renin in the afferent
arterioles obtained from the ramipril + L-NAME-treated animals
were reduced to levels similar to controls (Fig. 1).
To investigate if the inhibitory effect of L-NAME on renin
synthesis is specific to angiotensin-converting enzyme inhibition,
the RAS was activated with a different maneuver (furosemide
administration) in a separate group of animals. Furosemide
treatment did not affect systolic arterial pressure (124 6 vs.
1117 5 mm Hg). Renin release and tissue renin content were
increased two- to threefold in arterioles of the furosemide-treated
animals compared to control (renin release 18,345 2,056 vs.
5,658 502 ng/mg/hr, P < 0.01, and renin content 56,507 6,250
vs. 24,125 2,435 ng/mg/hr, P < 0.01; Fig. 2). Similarly, the
expression of renin mRNA was increased two- to threefold by
furosemide treatment (at 20 mg total RNA, 495 56 vs. 212 37
cpm, P < 0.01). As was the case with ramipril + L-NAME rats,
administration of L-NAME to the furosemide-treated rats sup-
pressed renin formation (renin release 7,150 717 ng/mg/hr;
renin content 30,520 3,245 ng/mg/hr, Fig. 2; renin mRNA 235
31 cpm).
Since the major physiological inhibitory mechanism of renin
activation is an increase in intracellular calcium concentration in
the renin producing cells, we examined whether blockade of
calcium entry in affcrent arterioles altered the effect of L-NAME
on the activation of renin synthesis. In these studies, nicardipine,
an L-type calcium channel blocker, was added to afferent arte-
rioles isolated from ramipril + L-NAME-trcated rats. As shown
in Figure 3A, nicardipine had no effect on renin release of
ramipril-treated animals. In sharp contrast, nicardipine canceled
Fig. 1. Renin secretion and total renin content (A) and mRNA levels (B)
from afferent arterioles isolated from control, ramipril- and ramipril +
L-N4 ME-treated rats. Values are means SEM of 5 experiments (4 to 6
rats/treatment/experiment). P < 0.05 versus control. Symbols in A are:
(•) control rats; () ramipril-treated rats; (l) ramipril + L-NAME-
treated rats. Symbols in B are: (•) control; (0) ramipril-treated rats; (LI)
ramipril + L-NAME-treated rats.
the inhibitory effect of L-NAME and completely restored renin
secretion to stimulated levels observed in ramipril-treated rats
(8,352 1,687 vs. 16,482 1,895 ng/mg/hr, P < 0.05 for ramipril
+ L-NAME-treated rats in absence and presence of nicardipine,
respectively). However, nicardipine had no effect on tissue renin
content (Fig. 3B). Contrary to changes of renin secretion that are
immediate, changes in renin synthesis are late phenomena. To
examine if renin transcription was reactivated by nicardipinc,
renin mRNA measurements were performed in afferent arterioles
isolated from ramipril + L-NAME-treated rats in the presence or
absence of nicardipine for four hours. As reported above, we
confirmed that expression of renin mRNA in the ramipril +
L-NAME group was threefold lower than in the ramipril group.
A
80000
60000
*
40000
20000
*
0
Secretion Total tissue content
E
z
a:
E
C
ci)
a:
B
800
600
400
200
$o
0 10 20 30
Total RNA, ,ig
**
C0
a)
C.)
a)(I)
C
C
a)
30000
A
Addition of nicardipine in these vessels for a period up to four
hours did not significantly change renin mRNA expression (data
not shown).
To gain insight into the mechanism(s) responsible for the
increased calcium entry occurring during the inhibition of NO in
affercnt arterioles, we investigated which agent increasing calcium
influx in vascular smooth muscle cells could be involved in the
inhibitory effect of L-NAME. Our results with ramipril excluded
the possibility that this agent was angiotensin II, because during
inhibition of converting enzyme the endogenous levels of angio-
tensin II are negligible. Another potential candidate was endo-
theliri, a potent vasoconstrictor and renin release inhibitor [17].
To test this hypothesis, bosentan, an antagonist of endothelin
receptors (ETA and ETB), was added to afferent arterioles
isolated from ramipril + L-NAME-treated rats. As shown in
Figure 4, bosentan mimicked the effect of nicardipine since it
canceled the inhibitory effect of L-NAME and completely re-
stored renin secretion to stimulated levels observed in ramipril-
treated rats (4,886 682 vs. 19,212 4,005 ng/mg/hr, P < 0.01 for
ramipril + L-NAME-treated rats in absence and presence of
bosentan, respectively, Fig. 4A). In the absence of L-NAME,
bosentan did not affect renin release of ramipril-treated rats (Fig.
4B). As was the case with nicardipine, bosentan had no effect on
tissue renin content (Fig. 4B).
The above results suggest that endothelin-induced calcium
influx could mediate the inhibitory effect of L-NAME on renin
synthesis. To verify whether this mechanism occurs in the whole
animal in vivo, rats were treated with ramipril and L-NAME
and/or bosentan. In vivo administration of bosentan had no effect
on systolic blood pressure (125 7 vs. 127 7 mm Hg, in
agreement with the literature for this dose and period of treat-
ment) [18, 191, or on renin release and synthesis (Fig. 5). Similarly,
hosentan did not change the systolic pressure of ramipril +
L-NAME-treated rats (130 7 vs. 134 6 mm Hg). In contrast,
in the vessels obtained from the ramipril + L-NAME + bosentan-
treated animals, renin release was increased twofold compared to
afferent arterioles isolated from ramipril + L-NAME-treated rats
(12,358 1,256 vs. 6,090 712 ng/mg/hr, P < 0.01, Fig. 5A).
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Fig. 2. Renin secretion (A) and total renin content (B) from afferent
arterioles isolated from control (U), furosemide- (E) and furosemide +
L-NAME-(f//i) treated rats. Values are means SEM of4 experiments. p <
0.05 versus control.
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Fig. 3. Renin secretion (A) and total renin content (B) from afferent
arterioles isolated from ramipril- and ramipril + L-NAME-treated rats in the
absence (U) and presence (Ikl) of 1 p.M of the calcium ently blocker,
nicardipine. Values are means SEM of5 experiments. *p < 0.05 versus
ramipril-treated group under control conditions.
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Fig. 4. Renin secretion (A) and total renin content (B) from afferent
arterioles isolated from ramipril- and ramipril + L-NAME-treated rats in the
(U) absence and (Iii) presence of] jtM of the endothelin receptor antagonist,
bosentan. Values are means SCM of 4 experiments. < 0.05 versus
ramipril-treated group under control conditions.
Interestingly, in vivo treatment with bosentan blunted the effect of
L-NAME on renin synthesis as evidenced from renin tissue
content (39,678 4,250 vs. 22,356 2,560 ng/mg/hr, P < 0.05,
Fig. SB). Similarly, bosentan-treatment altered the effect of
L-NAME on renin mRNA levels (1,315 110 vs. 642 67 cpm,
P < 0.01, at 20 mg of total RNA, Fig. 6). Note that treatment with
bosentan did not completely re-establish renin formation (renin
release 18,215 1,854 vs. 12,358 1,256 ng/mglhr, P < 0,05,
renin content 58,975 6,550 vs. 39,678 4,250 ng/mg/hr, P <
0.05, and renin mRNA levels 1,712 156 vs. 1,315 110 cpm,
P < 0.05, for ramipril + bosentan before and during L-NAME
treatment, respectively, Figs. 5 and 6). Thus, hosentan applied
chronically, but not acutely (Fig. 4), partially restored renin
transcription and synthesis. As mentioned above, changes in renin
synthesis are late phenomena, and the lack of stimulation of renin
synthesis in presence of bosentan or nicardipine in vitro was
probably due to time restraints.
Ramipril Ramipril + L-NAME
El
I
Fig. 5. Renin secretion (A) and total renin content (B) from afferent
arterioles isolated from ramipril-, ramipril + L-NAME-, ramipril + bosen-
tan- and ramipril + L-NAME + bosentan-treated rats. Values are means
SCM of 4 experiments. < 0.05 versus ramipril-treated group under
control conditions; #P < 0.05 versus ramipril + L-NAME + bosentan-
treated group. Symbols are: (•) without bosentan; (ii) with bosentan.
The present study provides new information about the mecha-
nism(s) regulating the activation of the renin formation, Specifi-
cally, our results highlight the importance of production of
endogenous NO as a mediator in this activation. Levels of mRNA,
tissue content and secretion of renin were measured under
conditions of activation of renin formation in the presence or
absence of pharmacological blockade of NO synthesis. Renin
synthesis was activated in vivo by two distinct mechanisms:
angiotensin-converting enzyme inhibition (angiotensin II depen-
dent) and salt transport inhibition (macula densa dependent). In
both cases, inhibition of NO synthesis by L-NAME blunted the
activation of renin synthesis. A novel finding was that the sup-
pressor effect of L-NAME was offset by nicardipine, a calcium
entry blocker, and by the endothelin receptor antagonist bosen-
tan. Thus, this study presents new evidence concerning the
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cellular mechanisms involved in the NO-RAS interaction. Our
results show that: (a) NO synthesis is necessary for the angiotensin
II- or macula densa-mediated activation of renin synthesis; (b) the
suppression of renin formation during NO inhibition is due to
increased calcium entry into the renin-producing cells; (c) at least
part of the increased calcium entry is mediated by endothelin.
Several experimental approaches have been used to investigate
whether or not NO influences renin release and/or synthesis.
Some investigators reported that inhibition of NO synthesis
stimulated renin release in rat cortical slices, conscious dogs and
anesthetized rats [2—4]. In contrast, other investigators found that
NO stimulated renin release in juxtaglomerular cultured cells,
isolated perfused kidney, anesthetized rats or conscious dogs
[5—8, 201. It is possible that NO originating from different cellular
sources may exert different effects on renin release. Consistent
with this notion, the effect of NO appears to be stimulatory or
inhibitory on renin secretion depending on the site of NO
production and on the target cells (macula densa cells, vascular
smooth muscle cells, NO applied on bath or lumen of isolated
perfused juxtaglomerular apparatus) [21—23].
Recently, we refined a preparation of freshly isolated afferent
arterioles to study regulation of the RAS [9—111. In this model it
is difficult to study the exact site of NO synthesis. However, this
vascular preparation offers some specific advantages. A more
representative population and a better homogeneization of affer-
ent arterioles can be achieved, because tissue from 4 to 6 rats per
condition/per experiment is pooled. The microvcssels are freshly
Fig. 6. A. Representative autoradiography of a RPA preprorenin mRNA
experiment. Ten, 20 or 30 .rg of RNA were obtained from afferent
arterioles of ramipril-, ramipril + L-NAME-, ramipril + bosentan- and
ramipril + L-NAME + bosentan-treated rats. B. Average values of
renin mRNA levels from afferent arterioles isolated from ramipril- (0),
ramipril + L-NAME- (•), ramipril + bosentan- (LII), and ramipril + L-
NAME + bosentan (U)-treated rats. Values are means SEM of 4
experiments.
isolated, thus excluding changes of cell phenotype. Finally, this
model is responsive to functional changes of renin regulation
resulting from an in vivo treatment, thus making feasible a
comprehensive evaluation of mechanisms governing renin activa-
tion in vivo [11].
The most intriguing observation of our recent studies was that
NO inhibition impaired the mechanism(s) controlling in vitro
stimulation of renin release [11]. The present studies extend this
initial observation to a more physiologically relevant content and
provide new insights into mechanisms involved in stimulation of
renin synthesis. In vivo treatment of animals with an angiotensin-
converting enzyme inhibitor strongly increased renin secretion,
renin synthesis and renin mRNA levels, which is in agreement
with previous studies on microdissected afferent arterioles and
whole kidney homogenates [14, 24J. Inhibition of NO synthesis by
L-NAME completely abolished the increase in renin rates of
transcription, synthesis and secretion. A similar inhibitory effect of
L-NAME on renin mRNA levels was previously observed in
whole kidneys obtained from rats treated with the ACE inhibitor,
perindopril [14]. Some of the suppression in renin activation may
have resulted from the L-NAME-induced increase in arterial
pressure. However, no correlation was observed between the
expression of renin mRNA levels and mean systolic pressure in
the L-NAME + ACE inhibitor-treated animals [14]. In conscious
rats, the pressure-dependent mechanism of renin release was
activated at values of arterial pressure < 95 mm Hg, whereas it
had little or no effect when arterial pressure was > 95 mm Hg [25].
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In addition, treatment with L-NAME exhibited the same suppres-
sion of RAS actLvity in the furosemide-treated rats (Fig. 2), where
no changes in arterial pressure were observed. These data imply
that the mechanism(s) by which L-NAME blocks renin stimula-
tion is (are) independent of systemic hemodynamic changes. It is
interesting to note that the inhibitory effect of L-NAME was
noted whether or not the activation of renin synthesis was due to
a reduction in endogenous angiotensin II levels (ramipril) or in
macula densa-mediated ion transport (furosemide). Similarly,
L-NAME inhibited the increase of renin mRNA expression in
whole kidneys of rats treated with an angiotensin receptor antag-
onist (losartan) or low sodium intake [7]. These findings strongly
suggest that NO inhibition interacts with renin activation at a
major step, one that seems to be common to these different
stimuli.
Since the major intracellular signal inhibitory to renin produc-
tin is an increase in cytosolic-free calcium concentration, we
evaluated the possibility that NO inhibition suppressed stimula-
tion of renin formation by increased calcium entry into the
renin-producing cells. The fact that nicardipine completely abol-
ished the L-NAME effect suggests that an increase in cytosolic
calcium concentration in afferent arterioles is mainly mediated by
calcium influx through voltage-sensitive L-type channels. The
existence of L-type calcium channels has been questioned in
cultured juxtaglomerular cells from mice [261. However, in the in
situ perfused rat kidney, Navar et al have observed that activation
of voltage-operated calcium channels is the major event leading to
calcium entry in afferent arterioles [27]. More recently it was
observed that L-type calcium channels mediate at least half of the
angiotensin IT-induced constriction in freshly isolated afferent
arterioles (preparation similar to ours) or in cultured vascular
smooth muscle cells obtained from afferent arterioles [281. Acute
application of nicardipine restored renin secretion, but not renin
synthesis or mRNA expression. It is possible that the kinetics of
renin secretion are much faster than those of renin synthesis, and
the time of exposure of arterioles to nicardipine (4 hr) was not
enough to elicit changes in mRNA levels. In support to this view,
increased renin secretion in response to forskolin was detected
almost immediately in cultured juxtaglomerular cells, whereas at
least three hours were required to observe increased levels of
mRNA [29].
Little is known about NO-mediated inhibition of calcium entry
in vascular smooth muscle or juxtaglomerular cells. It is reported
that NO-synthase inhibitors induced accumulation of intracellular
calcium in cultured vascular smooth muscle cells by reducing
protein kinase G activity [30]. Alternatively, NO could regulate
the function of ion channels directly without requiring cGMP. In
this regard, NO is reported to activate calcium-dependent potas-
sium channels in rabbit aorta irrespective of guanylate cyclase
activation [31]. An attractive hypothesis is that NO interferes with
the action of one or several agents, such as angiotensin II or
endothelin, stimulating calcium entry into smooth muscle cells.
Our data obtained with bosentan, an antagonist of endothelin
receptor, are in agreement with this hypothesis. Acute treatment
of afferent arterioles with bosentan mimicked the effect of nicar-
dipine and restored renin secretion to activated levels (Fig. 4). In
favor to this notion, recent reports indicate that endothelin
inhibited the cAMP-mediated activation of renin synthesis
through a calcium channel-dependent mechanism in juxtaglomer-
ular cells cultured in vitro [32, 33]. To verify whether the NO
inhibition-endothelin mechanism occurs in vivo, we coadminis-
tered L-NAME and/or bosentan with ramipril. Chronic treatment
with bosentan altered the effect of L-NAME and reactivated renin
synthesis, confirming our hypothesis. The fact that renin produc-
tion was partially restored could be due to dose restraints (we
used the minimum required to avoid hemodynamic effects) or to
another agent mediating calcium entry. If the latter was the case,
this agent would not be angiotensin II since L-NAME inhibited
activation of renin synthesis in ramipril-treated animals (where
synthesis of angiotensin II is blocked). This is in agreement with
the observation that the renal hemodynamic response to NO
inhibition is not mediated by endogenous angiotensin II in
conscious rats [341. In support of the NO-endothelin interaction
hypothesis, elevation of NO production reduced, whereas inhibi-
tion of NO increased expression of endothelin-1 transcription
levels in human endothelial cells [35], and NO antagonized the
endothelin receptor signaling by inhibiting calcium mobilization
in CHO transfected cells [36]. Similarly, the production of endo-
thelin from aortic vessels was inhibited in presence of NO and
potentiated during NO inhibition [37]. In addition, antagonism of
endothelin receptor A blunted the systemic and renal vasocon-
strictor effects produced during NO inhibition in anesthetized rats
[38]. In our model, it is possible that NO inhibition stimulated the
endothelin system (by increasing transcriptional rates of big-
endothelin mRNA, or by activating its intracellular signaling
pathway). Alternatively, it is possible that the endothelin system
was not activated, but its action became apparent because of the
absence of the counterbalancing action of NO. Whatever the case
is, the data obtained from ramipril + bosentan-treated animals
suggest that endothelin has no major effect on RAS in presence of
NO, whereas it mediates suppression of renin formation during
inhibition of NO synthesis.
In conclusion, the mechanisms that activate the renin synthesis
are not effective when endogenous NO synthesis is inhibited. The
cause of this defect is probably due to increased entry of calcium
into the renin-producing cells of afferent arterioles. This calcium
influx is, at least partly, mediated by the action of endothelin
presumably triggered by inhibition of NO synthesis. These data
indicate the importance of the balance between endothelial
vasodilators/vasoconstrictors in the physiological mechanisms
controlling the renin-angiotensin system.
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